



PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through 07/01/2017. GSA ECR #17-0357
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/603,129
Filing Date	June 24, 2003
First Named Inventor	Schuessler, David J.
Art Unit	1772
Examiner Name	Miggins
Attorney Docket Number	33915-03420

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		EP 0 947 899 A2	10-6-1999	A-Pear Biometric Rep.	col. 12, lines 35-54	
		GB 702,146	1-13-1954	The Chad Valley Co. Ltd	page 2, lines 12-16	
		GB 1,206,110	9-23-1970	Courtaulds Ltd.	pg 1:89 - pg 2:110	
		GB 1,192,360	5-20-1970	Courtaulds, Ltd.	pg 1, lines 35-54	
		GB 1,306,541	2-14-1973	Ceskoslovenska Akademie	pg 1:38 - pg 2:81	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT
Docket No.: 33915-03420

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : David J. Schuessler
Serial No. : 10/603,129 Group Art Unit : 1772
Filed : June 24, 2003 Examiner: Michael C. Miggins
For : ***ROTATIONALLY MOLDED MEDICAL ARTICLES***

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22314-1450

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO/SB/08B, a copy of which is enclosed, may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. [] For each of the following items listed on the enclosed copy of Form PTO/SB/08A/8B that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:

2. [] For each of the following items listed on the enclosed copy of Form PTO/SB/08A/8B that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.

3. [] Any copy of the items listed on the enclosed copy of Form PTO/SB/08A/8B that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in the prior [] Continuation, [] Divisional or [] Continuation-In-Part application under 37 C.F.R. §1.60, U.S. Serial No. _____, filed _____.

4. [X] No fee is due under 37 C.F.R. §1.17 for this Information Disclosure Statement since it is being filed in compliance with:

[] 37 C.F.R. §1.97(b)(1), within three months of the filing date of the above-identified application.

[] 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application.

[] 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits.

[X] 37 C.F.R. §1.97(b)(4), before the mailing of a first Office action after the filing of a request for continued examination under §1.114.

5. [] No fee is due under 37 C.F.R. §1.17 for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.

6. [] A fee is due under 37 C.F.R. §1.17 for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):

[] A check in the amount of \$180.00 is enclosed in payment of the fee.

[] Charge the fee to Deposit Account No. 13-3250. Order No. 33915-03420. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

7. [] A fee is due under 37 C.F.R. §1.17 for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:

a. one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and


b. the attached petition requesting consideration of this Information Disclosure Statement; and

c. the fee due under 37 C.F.R. §1.17 which is paid as set forth in paragraph 10 below.

8. [] A fee is due under 37 C.F.R. §1.17 for this Information Disclosure Statement since it is being filed in compliance with:

- a. [] 37 C.F.R. §1.313(b)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue;
- b. [] 37 C.F.R. §1.313(b)(5), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue.
- c. The fee due under 37 C.F.R. §1.17 is paid as set forth in paragraph 10 below.
9. [X] I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- [] I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
10. [] A check in the amount of \$180.00 is enclosed in payment of the fee due under 37 C.F.R. §1.17.
- [] Charge the fee due under 37 C.F.R. §1.17 to Deposit Account No. 13-3250. Order No. 33915-03420. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- [X] The Assistant Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-3250. Order No. 33915-03420. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MILBANK, TWEED, HADLEY & McCLOY LLP


James R. Klaiber
Reg. No.: 41,902

August 3, 2006

Milbank, Tweed, Hadley & McCloy LLP
1 Chase Manhattan Plaza
New York, NY 10005-1413

(212) 530-5000 / (212) 530-5219 (facsimile)
NY2:#4701747v1
08/3/06 10:40 AM